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RNA directed RNA polymerase of human
coronaviruses can be used as epitope-based
universal vaccine design
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Background: Coronaviruses are the diverse group of RNA virus. From 1960, six strains of human coronaviruses have
emerged that includes SARS-CoV and the recent infection by deadly MERS-CoV which is now going to cause
another outbreak. Prevention of these viruses is urgent and a universal vaccine for all strain could be a promising solution
in this circumstance. In this study we aimed to design an epitope based vaccine against all strain of human coronavirus.
Results: Multiple sequence alignment (MSA) approach was employed among spike (S), membrane (M), enveloped (E)
and nucleocapsid (N) protein and replicase polyprotein 1ab to identify which one is highly conserve in all coronaviruses
strains. Next, we use various in silico tools to predict consensus immunogenic and conserved peptide. We found that
conserved region is present only in the RNA directed RNA polymerase protein. In this protein we identified one epitope
WDYPKCDRA is highly immunogenic and 100% conserved among all available human coronavirus strains.
Conclusions: Here we suggest in vivo study of our identified novel peptide antigen in RNA directed RNA polymerase
protein for universal vaccine – which may be the way to prevent all human coronavirus disease.
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Coronaviruses are the diverse group of virus which in-
fects domestic animals, birds as well as human [1]. Coro-
naviruses are enveloped viruses which are the members
of Coronaviridae family [2]. Coronaviruses have positive
strand RNA genome which is approximately 26–32 kb
long. The overall structures of all coronaviruses are com-
posed of the spike (S), envelope (E), membrane (M) and
nucleocapsid (N) protein. The other non-structural pro-
teins like RNA directed RNA polymerase, helicase, 3CL
like proteinases etc are produced by the cleavage of replic-
ase polyprotein 1ab or ORF 1ab polyprotein [3].
The first coronavirus 229E was identified in 1960.
Since then different types of coronaviruses have emerged.
HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63,
HCoV-HKU1 and MERS-CoV are the coronaviruses which* Correspondence: khademul@du.ac.bd
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article, unless otherwise stated.infect human [4]. Most of the coronaviruses cause respira-
tory, enteric, hepatic, or neurological diseases with highly
variable severity in their hosts [5]. The first two coro-
navirus HCoV-229E and HCoV-OC43 infects lower re-
spiratory tract where the later SARS-CoV, HCoV-NL63,
HCoV-HKU1 infect both lower and upper respiratory
tract [4,6-8]. But the newly emerged MERS-CoV infects
both lung and kidney that reflects how these viruses are
changing their cell tropism and becoming highly patho-
genic [9].
Most infections caused by human coronaviruses were
relatively mild. Among all the human coronaviruses, SARS-
CoV and MERS-CoV are much more deadly. The severe
acute respiratory syndrome (SARS) outbreak caused
by SARS-CoV in 2002 to 2003. The SARS-CoV created
outbreak resulted in a total of 916 deaths among more
than 8000 confirmed cases in over 30 countries [10,11].
The newly emerged MERS-CoV is now posing a great
threat for human. According to WHO, 75 people have diedentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biomedcentral.com/1471-2105/15/161among more than 178 confirmed cases caused by MERS-
CoV [4]. Though this MERS-CoV virus was first found in
Saudi Arabia 2012, now it has been emerged in UK,
France, Tunisia, Spain and Italy that indicates it’s going to
create another outbreak like SARS-CoV [12-14]. From
1960 to till now there is no recommended drug or vaccine
for MERS-CoV infection and treatment relies on exclusively
supportive care, which gives the high case-fatality rate, is
not highly effective [15].
In 2003 after the discovery of SARS-CoV, there were a
significant increase in research on coronavirus, but noFigure 1 Conserved peptide in RNA directed RNA polymerase. Multipl
coronaviruses revealed that human coronaviruses are conserved in RNA dir
[25]. Along the alignment this tool provides a graphical (bar chart) conserv
for quality. For Conservation yellow color bar and star sign indicates the fu
color indicates good quality. All the colors changes according to the consedefinitive antiviral or therapeutic treatment for coronavirus
infections came from these researches [16]. From the
clinical experience of SARS-CoV found that a number
of interventions including ribavirin with and without
corticosteroids, ribavirin with protease inhibitors and
interferon with corticosteroids may improve outcome.
But a definitive treatment was not clearly established
and the therapeutic interventions have not been evalu-
ated in vivo [17].
The identification of therapeutics is a high priority and
though there is currently no specific therapy or vaccinee sequence alignment of the 46 replicase polyprotein 1ab of all
ected RNA polymerase. This alignment was visualized by Jalview 2.8
ation summery using 11-base scale for conservancy and BLOSUM 62
ll conservation. Black bars showed the consensus sequence and yellow
rvation and alignment quality.
Figure 2 Protein variability index of the conserved peptide. The protein variability index of the conserved peptide was determined by using PVS server
[24]. The conservancy threshold was 1.0 in this analysis. X axis indicates the amino acid position in sequences and Y axis indicates the Wu-kabat variability.
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a high case-fatality rate [18]. As these viruses are now be-
coming pathogenic and causing outbreaks, so steps have
to be taken to prevent human death. Vaccination is one of
the most efficient ways to prevent infectious disease [19].
Effective vaccines controlling virus spread and disease are
available for a number of infections, such as smallpox,
poliomyelitis, measles, mumps, rubella, influenza, hepatitis
A, and hepatitis B [20]. For coronavirus, this vaccine ap-
proach is hindered by the fact that human coronavirus
strains are not structurally related and they are changing
rapidly by recombination [21]. Therefore, designing a uni-
versal vaccine against conserved regions for all human
coronaviruses is a major challenge at present.Figure 3 Antigenicity of the conserved peptide. The conserved peptide wa
residues were found above the threshold 1.00. Residues in the yellow region arWith the disclosure of huge sequence information,
epitope based vaccine design now has become a most
promising approach for viral vaccine preparation [22]. In
order to prepare vaccines, computational prediction of
epitopes and vaccine design can reliably aid this process
to reduce time and cost. Although the epitope based
vaccine design is now a familiar concept, not much work
has been done in case of coronaviruses.
In this study, we design an epitope based universal vac-
cine which can be use to prevent all kind of human coro-
naviruses. For this, bioinformatics analyses of viral proteins
were done for finding the conserved peptide region and
for mapping the evolutionary conserved epitope. The
3D structure of RNA directed RNA polymerase wass found to be highly antigenic in the IEDB analysis [27]. Most of the
e antigenic and in the green region are below the threshold (red line).
Table 1 Predicted antigenic sites and their lengths using Bepipred [29] and IEDB [28] analysis tools
Bepipred analysis IEDB analysis
Peptide Length (aa) Peptide Length (aa)
VRPGNFNQ 8 DYKVQLFEKYFKY 13
GNAAIT 6 HANCVNCTDDRCVLHCANFNVLFAM 25
DKSAGHPFN 9 KTCFGPIVRKIFVDGVPFVVSCGYHYKELGLV 32
SYQEQ 5 VSLHRHRLSLK 11
DVDNP 5 ADPAMHI 7
YPKCDRA 7 SSNAFLDLRTSCFSVAALTTG 21















Table 2 Consensus antigenic sites between Bepipred [29]
and IEDB analysis [28] predicted antigenic sites
Consensus Epitope Length (aa)
YPKCDRA 7
YYVKPG 6
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highly immunogenic, accessible and conserved epitope
was identified. This epitope can be used as a universal
vaccine against all human coronaviruses.
Results
RNA directed RNA polymerase is highly conserved in all
human coronavirus strains
To find a conserved region, MSA by clustalW [23] and pro-
tein variability index [24] analyses were performed. No con-
served region was found in case of S, E, M and N proteins
(Additional file 1: Figure S1, Additional file 2: Figure S2,
Additional file 3: Figure S3, Additional file 4: Figure S4 re-
spectively). From the MSA of replicase polyprotein 1ab cor-
onaviruses were found to be conserved in RNA directed
RNA polymerase (Additional file 5: Figure S5). MSA of
this RNA directed RNA polymerase region (Figure 1)
and protein variability index (Figure 2) identified a 385
amino acid long conserved region among all human
coronaviruses. The conserve sequence was then used to
determine immunogenicity.
Both YPKCDRA and YYVKPG identified as consensus and
highly immunogenic epitopes by two different algorithms
For vaccine design the peptide has to be immunogenic
and antigenic [26]. The conserved peptide was found tobe highly antigenic (Figure 3) in IEDB epitope prediction
analysis [27]. In this analysis 1.000 threshold was used and
most of the residues in the peptides were found above
the threshold level. B-cell epitopes were predicted using
Immune Epitope Database (IEDB) [28] B-cell epitope pre-
diction tool and Bepipred [29] using the conserved protein
sequence. Several epitopes were predicted (Table 1) by
these algorithms, but only those epitopes sequences that
are found full or at least 90% overlap between IEDB B-cell
epitope prediction tool [28] and Bepipred prediction [29]
are chosen as desired epitopes (Table 2). YPKCDRA and
YYVKPG epitopes were found to be consensus among
both tools predicted epitopes.
Nine surface accessible epitopes were predicted from the
conserved peptide
To become a vaccine, an epitope should be accessible to
the antibody. If the antibody can bind to the epitope that
will be able to induce an immune response [26]. The
Figure 4 Conserved peptide’s surface accessibility. The surface accessible residues of the conserved peptide which are above the cut off are
located in the yellow region. The red horizontal line indicates surface accessibility cutoff (1.000).
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http://www.biomedcentral.com/1471-2105/15/161surface accessibility of the conserved peptide (Figure 4)
was determined using 1.000 threshold level and nine ac-
cessible epitopes were found to be above the threshold
level (Figure 4) (Table 3) using Immune Epitope Data-
base (IEDB) [28] Emini surface accessibility prediction
analysis [30]. Among these nine epitopes, WDYPKC epi-
tope overlaps with the Bepipred [29] and IEDB [28] pre-
dicted consensus epitope YPKCDRA.
WDYPKCDRA is fully conserved among all human corona
virus isolates
The conservancies of all epitopes were determined by
IEDB conservancy analysis tools [31]. From the IEDB pre-
dicted epitopes, two epitopes (YPKCDRA, LKYAIS) and
from Bepipred predicted epitopes, YPKCDRA epitope were
found to be 100% conserved among all human coronavirus
isolates (Table 4). WDYPKC epitope from the surface
accessible epitope was also found to be 100% conserved
(Table 4). Among the two consensus epitopes of BepipredTable 3 Predicted surface accessible antigenic sites by










TRDRFY 6[29] and IEDB [28] analysis, YPKCDRA epitope was found
to be 100% conserved among all human coronavirus iso-
lates (Figure 5). This YPKCDRA and WDYPKC epitopes
are in the same region and 100% conserved in all human
coronaviruses. Therefore, the whole epitope WDYPKC-
DRA which is 100% conserved was then selected as the de-
sired universal vaccine candidate.WDYPKCDRA is also an accessible epitope
Hydrophilicity is desired feature of B cell epitope which
indicates the accessibility of the epitope. The WDYPKC-
DRA epitope was found to be hydrophilic (Figure 6) in
nature as determined by the IEDB Parker hydrophilicity
analysis [32]. A threshold of 3.448 was used which is in-
dicated by the red line and the residues of the epitope
which are hydrophilic are in the yellow region. The max-
imum level was found as 4.5 (Figure 6) in the epitope.A tertiary structure of RNA directed RNA polymerase was
predicted and validated using in silico approach
As the experimental tertiary structure of the RNA di-
rected RNA polymerase is not available, we modeled a
3D structure by I-TASSER server [33] by multiple threading
alignments. I-TASSER analysis deduced 5 different models
(data not shown) for this protein. The quality of all the
predicted protein models was checked by PROCHECK
analysis [34]. From the PROCHECK analysis results, the
protein model in which maximum numbers of amino
acids residues were in maximum favorable region and G
factor was highest was taken as the desired best model.
The model in which 89.3% residues are found to be in
the most favored region in Ramachandran plot (Additional
Table 4 Predicted conservancy of the antigenic site by
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http://www.biomedcentral.com/1471-2105/15/161file 6: Figure S6) and G-factor was −0.31 from the PRO-
CHECK analysis was selected as the desired model. Along
with the surface accessibility analysis and hydrophilicity
analysis, the targeted WDYPKCDRA epitope was also
found to be in the surface and accessible in the RNAdirected RNA polymerase 3D structure (marked as green
color) (Figure 7).
Discussion
Coronaviruses are one of the most diverse groups of virus
which are becoming a deadly virus day by day. Though
the first two strains were not so much deadly but the other
members were pathogenic. After SARS outbreak, a new
coronavirus strain called MERS-CoV is now going to
cause another outbreak [4]. The cell tropism and cellular
receptor of the six types of coronaviruses are not similar
(Additional file 7: Table S1). Though at first it was thought
that SARS-CoV and MERS-CoV are structurally similar
and tried to treat MERS-CoV infected patient with the
SASR-CoV treatment. But it was found that they bind to
two different receptors, namely ACE2 and DPP4 or CD26
respectively [36]. These viruses are actually zoonotic
origin, undergo recombination, and may be in future an-
other strain of this group of virus will come [37]. There-
fore, it is important to take preventing measures not only
to prevent this new strain of coronavirus, also against all
the strain of coronavirus. There is no recommended vac-
cine for coronaviruses which is necessary to prevent. Most
of the cases, vaccines were designed by targeting spike pro-
tein. Similarly, researchers also reported to design vaccine
against SARS-CoV and MERS-CoV spike protein [38,39].
Fernando et al. also designed lived-attenuated MERS cor-
onavirus by mutating MERS-CoV envelope protein as a
vaccine which will be for only MERS-CoV [40]. These vac-
cines would thus be effective for only those strains not for
others. Giving a universal vaccine for all strain of viruses is
much more promising solution rather than giving individ-
ual vaccine for individual strain.
The concept of prevention of viruses by designing a uni-
versal vaccine has also been reported previously, for ex-
ample against Influenza virus. In case of influenza virus,
universal vaccine against matrix 2 protein which was found
to be conserved among all Influenza subtypes was reported
[41]. An attempt to design universal vaccine against mem-
bers of coronaviruses, like feline infectious peritonitis
(FIPV), canine coronavirus (CCV), gastroenteritis corona-
virus (TGEV), bovine coronavirus (BCV) targeting their
spike protein in 1993 were observed [42]. But this concept
was not applied to human coronaviruses.
Vaccine development has been one of the most im-
portant contributions of immunology to public health
to date. Traditionally vaccines were based on the intact
pathogen, either inactivated or live attenuated. These
types of vaccines had some crucial drawbacks like safety
consideration and the loss of efficacy due to the genetic
variation of the pathogen. But now a day’s these vaccine
concepts are greatly replaced by novel vaccine approaches
like naked DNA vaccine, epitope based vaccine. The main
benefit of immunization with an epitope-based vaccine is
Figure 5 Conservancy of the predicted consensus epitopes. Three of the four epitopes were found to be 100% conserved. Here Y axis
indicates the epitopes and X axis indicates the conservancy percentage.
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will stimulate an effective specific immune response, while
avoiding potential undesirable effects [43].
In this study, we aimed to design an epitope-based uni-
versal vaccine for all human coronavirus strain. For this
purpose we did multiple sequence alignment of the spike
(S), envelope (E), membrane (M), nucleocapsid (N) protein
and replicase polyprotein 1ab of all six human coro-
naviruses. Replicase polyprotein 1ab was taken to check
whether there is any conservancy among the non struc-
tural protein as this replicase polyprotein cleaved into 15
non-structural proteins. In case of S, E, M and N protein,
no putative conserved region was found. But conserved re-
gion was found in case of replicae polyprotein 1ab where
the conserved region was in the RNA directed RNA
polymerase. This indicates that this protein is less mutating
than the S, E, M and N protein. This RNA directed RNA
polymerase protein was targeted to determine antigenic
sites based on immunogenicity and surface accessibilityFigure 6 Hydrophilicity of the WDYPKCDRA epitope. Most of the resid
in nature (in the yellow colored region). The residues which are below theusing different bioinformatics analyses. The consensus
antigenic sites were the desired one and their conservancy
was also determined. From the conservancy analysis it was
found that Bepipred [29] and IEDB [28] analysis predicted
consensus epitope YPKCDRA and the surface accessibility
analysis [30] predicted epitope WDYPKC are 100% con-
served. This 100% conserved WDYPKC and YPKCDRA
are actually located in the same region of RNA directed
RNA polymerase and it was then taken as the targeted
epitope. This epitope was found to be accessible and
hydrophilic which is one of the crucial requirements for
an epitope to be used as a vaccine. This reflects a promis-
ing scope to use this conserved epitope as a universal vac-
cine both as preventive and therapeutic treatment. As this
epitope remain long been conserved since 1960, it may be
possible to use this vaccine in future for upcoming human
coronavirus strains as well. To become an effective vac-
cine, it needs to be highly immunogenic, stable inside the
body. If it is poorly immunogenic or unstable, it needs toues of the desired WDYPKCDRA epitope were found to be hydrophilic
cut off 3.448 (red line) are in the green region.
Figure 7 3D structure of RNA directed RNA polymerase protein.
Predicted conserved WDYPKCDRA epitope mapped onto protein 3D
structure using UCSF Chimera [35] visualization tool. Here green
colored region indicates the conserved epitope WDYPKCDRA.
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http://www.biomedcentral.com/1471-2105/15/161be conjugated with adjuvant [44]. Though this epitope
based vaccine is designed by in silico analyses, the actual
immunogenicity, stability, efficacy and their delivery strat-
egy inside the recipients body can’t be determined by this
in silico analysis. To address these questions in vitro and
in vivo experiments are essential.
Conclusions
This study shows that though the human coronaviruses
are not structurally related but it is possible to design an
epitope-based universal vaccine for all human corona-
virus strains. Our results are based on sequence analysis
and computational predictions show predicted epitope
would be a candidate target for the universal vaccine;
and to determine the actual effectiveness of the peptide
for mounting an immune response both in vitro and
in vivo studies can be performed.
Methods
Retrieving coronavirus structural and nonstructural
protein sequences
A total available 46 replicase polyprotein 1ab, 17 spike (S)
protein, 18 envelope (E) protein, 18 membrane (M) and18 nucleocapsid (N) protein sequence data were retrieved
from NCBI GenBank sequence database [45] (Additional
file 7: Table S1).
Identification of conserved region
To find the conserved region, retrieved sequences were
aligned using EBI-clustalW program [23]. This multiple
sequence alignment (MSA) was done with Gonnet matrix
[23]. Protein variability server (PVS) was used to calculate
protein variability index using Wu-kabat Variability coeffi-
cient [24]. From the multiple sequence alignment where
the highest number of identical and similar amino acid
and no gap was found, the sequence was selected as a con-
served region. That conserved region was then used for
antigenic site prediction.
Detection of immunogenicity of conserved peptides
To evaluate the immunogenicity of the conserved pep-
tides, various bioinformatics algorithms and compu-
tational tools were used. Bepipred (v1.0) [29] and B cell
epitope prediction tools of The Immune Epitope Data-
base (IEDB) [28] were used for this purpose. Bepipred
predicts linear B-cell epitopes using hidden Markov
model [29]. Default threshold 0.35 was used for Bepipred
analysis. Among B cell epitope prediction tools of IEDB,
prediction of linear epitopes from protein sequence tool
was used. The Immune Epitope Database (IEDB) linear
epitope prediction tools [28] made the option of using
different prediction methods. Finally Kolaskar and Ton-
gaonkar Antigenicity method [27] was applied in this study
using a threshold of 1.000 because it predicts the antigenic-
ity of the provided protein sequence. The epitopes which
were found to be fully or at least 90% overlap between
IEDB B-cell epitope prediction tool [28] and Bepipred pre-
diction [29] are chosen as desired epitope sequences.
Prediction of surface accessible epitopes
To predict the surface accessible epitope of the conserved
peptide, Emini surface accessibility prediction tool [30] of
the B cell epitope prediction tools of The Immune Epitope
Database (IEDB) [28] was used for this purpose using de-
fault threshold level 1.0.
Prediction of epitope conservancy
The epitope conservancy analysis tool from the IEDB ana-
lysis resource was employed for epitope conservancy pre-
diction [31] of all predicted epitopes. The conservancy
level of the epitopes were calculated by searching for iden-
tities in the given protein sequence.
Prediction of epitope hydrophilicity
The conserved epitope was then also analyzed to deter-
mine the hydrophilicity of the predicted epitopes. Parker
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Database (IEDB) [28] was used for this purpose and de-
fault threshold 3.448 was used.Prediction and evaluation protein 3D model
As the experimental structure of RNA directed RNA poly-
merase protein of any human coronavirus isolate was not
found in protein data bank (PDB), a 3D structure was pre-
dicted using I-TASSER server [33]. I-TASSER server gives
protein 3D structure by multiple threading alignments
[33]. I-TASSER provided top models quality was then veri-
fied by PROCHECK software [34]. The model for which G
factor was highest, and amino acid residues in favorable
region was higher in PROCHECK analysis was selected as
the best model. This model was then used to locate the
epitope by using UCSF Chimera [35] visualization tool.Additional files
Additional file 1: Figure S1. Multiple sequence alignment of Spike (S)
protein: Multiple sequence alignment of total 17 numbers of sequences
of human coronaviruse isolates indicate that there is no conservation in
their spike protein. This alignment was visualized by Jalview 2.8 [25] and
color scheme used is Clustalx. Conservation showed here is based on 11
base scales where yellow color bar and star sign indicates the full
conservation. Alignment quality was based on BLOSUM 62 substitution
matrix score where yellow color indicates good quality. All the colors
changes according to the conservation and alignment quality. Black bars
showed the consensus sequence.
Additional file 2: Figure S2. Multiple sequence alignment of envelope
(E) protein: Figure legend as in supplementary Figure S1.
Additional file 3: Figure S3. Multiple sequence alignment of
membrane (M) protein: Figure legend as in supplementary Figure S1.
Additional file 4: Figure S4. Multiple sequence alignment of
nucleocapsid (N) protein: Figure legend as in supplementary Figure S1.
Additional file 5: Figure S5. Conserved peptide found in RNA directed
RNA polymerase by multiple sequence alignment of replicase polyprotein
1ab: All human coronaviruses are found to be conserved in their
replicase polyprotein 1ab.
Additional file 6: Figure S6. Ramachandran plot for RNA directed RNA
polymerase protein: Red colored region is the most favored region,
brown and yellow colored regions are additionally allowed region and
generously allowed regions respectively.
Additional file 7: Table S1. Sequence sources and other sequence
related information.Abbreviations
HCoV: Human coronavirus; SARS: Severe acute respiratory syndrome;
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